Please complete the CAPTCHA to continue
@fda.gov
✓
LinkedIn matched
A concise factual answer block for searchers comparing this professional profile.
John Kadavil, Ph.D. is listed as Pharmacologist at FDA, a company with 14770 employees, based in Washington DC-Baltimore Area, United States, United States. AeroLeads shows a work email signal at fda.gov and a matched LinkedIn profile for John Kadavil, Ph.D..
John Kadavil, Ph.D. previously worked as Clinical Pharmacologist at Fda and Deputy Division Director (Supervisory Pharmacologist) at Fda. John Kadavil, Ph.D. holds Ph.D., Molecular Pharmacology & Toxicology from University Of Maryland School Of Medicine.
This section adds company-level context without repeating John Kadavil, Ph.D.'s masked contact details.
AeroLeads found 1 current-domain work email signal for John Kadavil, Ph.D.. Compare company email patterns before reaching out.
Pharmacologist at the U.S. Food and Drug Administration (FDA), with 20 years of experience in the regulatory compliance and technical aspects of bioavailability (BA), bioequivalence (BE), pharmacokinetic (PK), pharmacodynamic (PD), immunogenicity and clinical endpoint studies supporting INDs, NDAs, ANDAs and BLAs. Recognized as a subject matter expert by industry in regulations of bioequivalence, bioavailability, and GLP studies.
Listed skills include Hplc, Glp, Ind, Molecular Biology, and 16 others.
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
CDER/Office Of Study Integrity & Surveillance
Under the Collaboration, Risk Evaluation & Surveillance Team (CREST) in OSIS, conducting risk-based selections of study sites for inspections. These sites conduct bioavailability, bioequivalence, pharmacokinetic, clinical endpoint, pharmacodynamic and immunogenicity studies supporting INDs, NDAs, ANDAs and BLAs.
CDER/Office Of Clinical Pharmacology/Division Of Cancer Pharmacology I
Reviewed clinical pharmacology data supporting the following IND submission types: Original IND/First in human study protocol, End of Phase I, Breakthrough Therapy Designation Request, Research IND, Clinical Hold Complete Response, Pre-IND, Pre-sBLA, Protocol Amendment, Parallel Scientific Advice. Served as primary clinical pharmacology reviewer for NDA..
CDER/Office Of Study Integrity & Surveillance
Deputy Director for the generic drug division in FDA OSIS that conducts regulatory inspections (domestic and international) of bioavailability, bioequivalence, pharmacokinetic, pharmacodynamic and immunogenicity studies supporting INDs, NDAs, ANDAs and BLAs.
CDER/Office Of Study Integrity & Surveillance
As Team Lead for the Collaboration, Risk Evaluation & Surveillance Team (CREST) in OSIS, oversaw and conducted risk-based selections of study sites for inspections. These sites conducted bioavailability, bioequivalence, pharmacokinetic, pharmacodynamic and immunogenicity studies supporting INDs, NDAs, ANDAs and BLAs.
CVM/Office Of New Animal Drug Evaluation
In the Division of Human Food Safety, reviewed tissue residue depletion studies and food use authorizations supporting veterinary drug applications for brand and generic products. Also reviewed tissue residue data, bioanalytical data, bioanalytical method validations, study designs and analytical method SOPs.
CDER/Office Of Compliance/Division Of Scientific Investigations
Conducted regulatory inspections (domestic and international) for bioequivalence, bioavailability, pharmacokinetic, pharmacodynamic and immunogenicity studies that supported drug INDs, NDAs, ANDAs and BLAs.
Other employees you can reach at fda.gov. View company contacts for 14770 employees →
Rongping Zeng
Colleague at Fda
Washington DC-Baltimore Area, United States
View →
JP
Johnny Pham
Colleague at Fda
Silver Spring, Maryland, United States, United States
View →
GC
Geoffrey Clark
Colleague at Fda
Rockville, Maryland, United States, United States
View →
CH
Christine Hatfield
Colleague at Fda
Everett, Washington, United States, United States
View →
AD
Andre D.
Colleague at Fda
Bear, Delaware, United States, United States
View →
JL
Jill Lindstrom
Colleague at Fda
Bethesda, Maryland, United States, United States
View →
LT
Larry Tolson
Colleague at Fda
Germantown, Maryland, United States, United States
View →
EA
Esther Allred
Colleague at Fda
Washington DC-Baltimore Area, United States
View →
KM
Kyisha Mcneil
Colleague at Fda
Glen Burnie, Maryland, United States, United States
View →
JL
James L. Kenney
Colleague at Fda
Rockville, Maryland, United States, United States
View →
Quick answers generated from the profile data available on this page.
John Kadavil, Ph.D. works for FDA.
John Kadavil, Ph.D. is listed as Pharmacologist at FDA.
AeroLeads has found 1 work email signal at @fda.gov for John Kadavil, Ph.D. at FDA.
John Kadavil, Ph.D. is based in Washington DC-Baltimore Area, United States, United States while working with FDA.
John Kadavil, Ph.D. has worked for Fda.
John Kadavil, Ph.D.'s colleagues at FDA include Rongping Zeng, Johnny Pham, Geoffrey Clark, Christine Hatfield, and Andre D..
You can use AeroLeads to view verified contact signals for John Kadavil, Ph.D. at FDA, including work email, phone, and LinkedIn data when available.
John Kadavil, Ph.D. holds Ph.D., Molecular Pharmacology & Toxicology from University Of Maryland School Of Medicine.
John Kadavil, Ph.D. is listed with skills including Hplc, Glp, Ind, Molecular Biology, Proteomics, Peptides, Biochemistry, and Drug Development.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contacts